Prof. Bernhard Baune
Universität Münster, Germany & University of Melbourne, Australia
| Talk | Predicting clinical response to ECT using omics techniques |
| Date | Thursday, April 20th, 2023 |
| Time | 18:00 - 18:45 |
| Round Table 1 | Precision neuromodulation in psychiatric disorders: from ancient to novel therapies |
BIOGRAPHY
Prof. Bernhard Baune (PhD, MD, MPH, MBA, FRANZCP) holds a Professorial Chair of Psychiatry, is Head of the Department of Psychiatry and the Director of the Laboratory Division of Molecular Neurobiology of Mental Health at the University of Münster, Münster, Germany since 2019. Previously, Prof. Baune has been the Cato Chair and Head of Department of Psychiatry at the University of Melbourne, Australia. Prof. Baune is a Fellow of the Royal Australian and New Zealand College of Psychiatrist (FRANZCP), he is a Professorial Fellow of the Department of Psychiatry, University of Melbourne and also at the Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Australia.
Prof. Baune is known for his extensive research program into the neurobiology of severe mental illness and treatment response, specifically in mood disorders, cognitive dysfunction and neuropsychiatry. He developed novel concepts and approaches in personalised psychiatry, molecular psychiatry, prediction and biomarker research and pharmacological treatment research. He is also well known for key research achievements in the field of the immune-neurobiology of psychiatric disorders.
He is currently the Lead PI of two EU funded projects that investigate the neurobiology and molecular foundations of treatment response (EraPerMed: PROMPT consortium) in major depressive disorder and the early detection and early treatment of treatment resistance in major psychiatric disorders (MDD, Bipolar disorder, Schizophrenia) (Horizon Europe: Psych-STRATA consortium). Moreover, he is the chair of the ECNP European network Pharmacogenomics and Transcriptomics of Neuropsychiatric Disorders. In addition, he leads the International consortium on the genomics of severe depression and response to ECT in affective disorders (GenECT-ic). His research approach aims at the discovery of novel treatment targets and eventually at personalising treatments in order to make real-world differences to the lives of people with mental illness.
His research is nationally and internationally widely recognized, has been funded by >35 Million Euros (e.g., NHMRC - Australia, EU EraPerMed, Horizon Europe, DFG –Germany) and he has published more than >655 peer-reviewed articles, reviews and book chapters (H-Index 87; >50,000 citations; Science, Nature, Lancet, Nature Genetics, N Eng J Med, JAMA Psychiatry, Lancet Psychiatry, Mol Psychiatry, Biol Psychiatry, Neuropsychopharmacology). He edited several textbooks in Psychiatry, and most recently the books “Personalised Psychiatry” (Elsevier), “Inflammation and Immunity of Depression” (Elsevier) and “Cognitive Dimensions of Major Depressive Disorder” (Oxford University Press).
Prof. Baune is known for his extensive research program into the neurobiology of severe mental illness and treatment response, specifically in mood disorders, cognitive dysfunction and neuropsychiatry. He developed novel concepts and approaches in personalised psychiatry, molecular psychiatry, prediction and biomarker research and pharmacological treatment research. He is also well known for key research achievements in the field of the immune-neurobiology of psychiatric disorders.
He is currently the Lead PI of two EU funded projects that investigate the neurobiology and molecular foundations of treatment response (EraPerMed: PROMPT consortium) in major depressive disorder and the early detection and early treatment of treatment resistance in major psychiatric disorders (MDD, Bipolar disorder, Schizophrenia) (Horizon Europe: Psych-STRATA consortium). Moreover, he is the chair of the ECNP European network Pharmacogenomics and Transcriptomics of Neuropsychiatric Disorders. In addition, he leads the International consortium on the genomics of severe depression and response to ECT in affective disorders (GenECT-ic). His research approach aims at the discovery of novel treatment targets and eventually at personalising treatments in order to make real-world differences to the lives of people with mental illness.
His research is nationally and internationally widely recognized, has been funded by >35 Million Euros (e.g., NHMRC - Australia, EU EraPerMed, Horizon Europe, DFG –Germany) and he has published more than >655 peer-reviewed articles, reviews and book chapters (H-Index 87; >50,000 citations; Science, Nature, Lancet, Nature Genetics, N Eng J Med, JAMA Psychiatry, Lancet Psychiatry, Mol Psychiatry, Biol Psychiatry, Neuropsychopharmacology). He edited several textbooks in Psychiatry, and most recently the books “Personalised Psychiatry” (Elsevier), “Inflammation and Immunity of Depression” (Elsevier) and “Cognitive Dimensions of Major Depressive Disorder” (Oxford University Press).